凝血因子XIII检测的研究进展*

doi:10.3969/j.issn.1671-2587.2024.04.023

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (4): 570-576.DOI: 10.3969/j.issn.1671-2587.2024.04.023

• 综述 • 上一篇

凝血因子XIII检测的研究进展^*

赵娅菲, 黄雨薇, 李长清, 蒋鹏, 马莉

中国医学科学院北京协和医学院输血研究所,四川成都 610052

收稿日期:2024-06-26 出版日期:2024-08-20 发布日期:2024-09-23
通讯作者: 蒋鹏,主要从事血栓与止血相关研究,（E-mail）peng_jiang2014@163.com。马莉, 主要从事血液成分的安全性与有效性方面研究,（E-mail）mary19820225@163.com。
作者简介:赵娅菲,主要从事输血医学方面研究,（E-mail）sophia@pumc.edu.cn。
基金资助:
*本课题受四川省科技计划项目（No.2022YFS0010）资助

Received:2024-06-26 Online:2024-08-20 Published:2024-09-23

摘要/Abstract

摘要： 凝血因子XIII（FXIII）作用于凝血过程的末端,能够稳定纤维蛋白,避免凝块过早降解,对于维持止血至关重要。FXIII缺乏症是一种罕见的出血性疾病,可导致危及生命的出血,因此FXIII的检测方式对于遗传性和获得性FXIII缺乏症的诊断具有重要意义。实验室常规的凝血试验无法检测并诊断FXIII缺乏,故而需要有针对性的进一步评估。目前国内可用于FXIII缺乏症的实验室诊断的测定大致包括凝块溶解度测定、FXIII活性测定、FXIII抗原测定、分子遗传分析、凝胶电泳（SDS-PAGE）、FXIII自身抗体检测。其中,灵敏度较差的凝块溶解度测定方式,目前仍在我国和许多国家广泛应用。本文总结了目前常见的FXIII检测方式及检测原理,讨论了不同方法的优点和局限性,介绍了国际推荐的检测流程,有助于临床依据实际情况选用合理科学的检测方式,从而提高诊断水平。

中图分类号:

R457

赵娅菲, 黄雨薇, 李长清, 蒋鹏, 马莉. 凝血因子XIII检测的研究进展^*[J]. 临床输血与检验, 2024, 26(4): 570-576.

参考文献

[1] MUSZBEK L,BERECZKY Z,BAGOLY Z,et al. Factor XIII :a coagulation factor with multiple plasmatic and cellular functions[J]. Physiol Rev,2011,91(3):931-972.
[2] LAWRIE A S,GREEN L,MACKIE I J,et al. Factor XIII —an under diagnosed deficiency—are we using the right assays?[J]. J Thromb Haemost,2010,8(11):2478-2482.
[3] WATANABE H,MOKUDA S,TOKUNAGA T,et al.Expression of factor XIII originating from synovial fibroblasts and macrophages induced by interleukin-6 signaling[J]. Inflamm Regen,2023,43(1):2.
[4] SCHROEDER V,KOHLER H P. Factor XIII :structure and function[J]. Semin Thromb Hemost,2016,42(4):422-428.
[5] BYRNES J R,LEE T,SHARABY S,et al.Reciprocal stabilization of coagulation factor XIII -A and-B subunits is a determinant of plasma FXIII concentration[J]. Blood,2024,143(5):444-455.
[6] CURTIS C G,BROWN K L,CREDO R B,et al.Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor[J]. Biochemistry,1974,13(18):3774-3780.
[7] KARIMI M, BERECZKY Z, COHAN N,et al. Factor XIII deficiency[J].British Journal of Haematology, 2009, 35(04):426-438.
[8] MARTA-ENGUITA J,NAVARRO-OVIEDO M,MACHADO F J D M,et al. Role of factor XIII in ischemic stroke:a key molecule promoting Thrombus stabilization and resistance to Lysis[J]. J Thromb Haemost,2024,22(4):1080-1093.
[9] DANG Y,ZHANG Y,JIAN M H,et al.Advances of blood coagulation factor XIII in bone healing[J]. Tissue Eng Part B Rev,2023,29(6):591-604.
[10] KAARTINEN M T,ARORA M,HEINONEN S,et al.F13A1 transglutaminase expression in human adipose tissue increases in acquired excess weight and associates with inflammatory status of adipocytes[J]. Int J Obes,2021,45(3):577-587.
[11] RICHARDSON V R,CORDELL P,STANDEVEN K F,et al.Substrates of factor XIII -A:roles in thrombosis and wound healing[J]. Clin Sci,2013,124(3):123-137.
[12] INBAL A,LUBETSKY A,KRAPP T,et al.Impaired wound healing in factor XIII deficient mice[J]. Thromb Haemost,2005,94(2):432-437.
[13] DARDIK R,LOSCALZO J,INBAL A. factor XIII (FXIII) and angiogenesis[J]. J Thromb Haemost,2006,4(1):19-25.
[14] ICHINOSE A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control[J]. Int J Hematol,2012,95(4):362-370.
[15] WEI Z M,GROENEVELD D J,ADELMEIJER J,et al.Coagulation factor XIII is a critical driver of liver regeneration after partial hepatectomy[J]. J Thromb Haemost,2024,22(3):620-632.
[16] ODAME J E,CHAN A K,WU J K,et al. Factor XIII deficiency management:a review of the literature[J]. Blood Coagul Fibrinolysis,2014,25(3):199-205.
[17] DORGALALEH A,NADERI M,HOSSEINI M S,et al. Factor XIII deficiency in Iran:a comprehensive review of the literature[J]. Semin Thromb Hemost,2015,41(3):323-329.
[18] KATONA É,PÉNZES K,MOLNÁR É,et al. Measurement of factor XIII activity in plasma[J]. Clin Chem Lab Med,2012,50(7):1191-1202.
[19] DORGALALEH A,NADERI M,SHAMSIZADEH M.Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency[J]. Ann Hematol,2016,95(3):451-455.
[20] MUSZBEK L,BAGOLY Z,CAIRO A,et al.Novel aspects of factor XIII deficiency[J]. Curr Opin Hematol,2011,18(5):366-372.
[21] MUSZBEK L,KATONA É.Diagnosis and management of congenital and acquired FXIII deficiencies[J]. Semin Thromb Hemost,2016,42(4):429-439.
[22] ESHGHI P,COHAN N,LAK M,et al.Arg77His and Trp187Arg are the most common mutations causing FXIII deficiency in Iran[J]. Clin Appl Thromb Hemost,2012,18(1):100-103.
[23] SHETTY S,SHELAR T,MIRGAL D,et al.Rare coagulation factor deficiencies:a countrywide screening data from India[J]. Haemophilia,2014,20(4):575-581.
[24] BISWAS A,IVASKEVICIUS V,SEITZ R,et al.An update of the mutation profile of Factor 13 A and B genes[J]. Blood Rev,2011,25(5):193-204.
[25] GHANSAH H,ORBÁN-KÁLMÁNDI R,DEBRECENI I B,et al. Low factor XIII levels and altered fibrinolysis in patients with multiple myeloma[J]. Thromb Res,2024,234:12-20.
[26] SCHROEDER V.Laboratory assessment of coagulation factor XIII [J]. Hamostaseologie,2020,40(4):467-471.
[27] DORGALALEH A,TABIBIAN S,HOSSEINI M S,et al.Diagnosis of factor XIII deficiency[J]. Hematology,2016,21(7):430-439.
[28] DORGALALEH A,TABIBIAN S,ASSADOLLAHI V,et al.Comparison of 2 methods of clot solubility testing in detection of factor XIII deficiency[J]. Lab Med,2016,47(4):283-285.
[29] ANWAR R,MILOSZEWSKI K J. Factor XIII deficiency[J].Br J Haematol,1999,107(3):468-484.
[30] FRANCIS J L.The detection and measurement of factor XIII activity:a review[J]. Med Lab Sci, 1980,37(2):137-147.
[31] DORGALALEH A,FARSHI Y,ALIZADEH S H,et al.Challenges in implementation of ISTH diagnostic algorithm for diagnosis and classification of factor XIII deficiency in Iran[J]. J Thromb Haemost, 2015,13(9):1735-1736.
[32] KOHLER H P,ICHINOSE A,SEITZ R,et al.Diagnosis and classification of factor XIII deficiencies[J]. J Thromb Haemost,2011,9(7):1404-1406.
[33] KARIMI M,PEYVANDI F,NADERI M,et al. Factor XIII deficiency diagnosis:Challenges and tools[J]. Int J Lab Hematol,2018,40(1):3-11.
[34] MUSZBEK L,POLGÁR J,FÉSÜS L. Kinetic determination of blood coagulation factor XIII in plasma[J]. Clin Chem,1985,31(1):35-40.
[35] FICKENSCHER K,AAB A,STÜBER W. A photometric assay for blood coagulation factor XIII [J]. Thromb Haemost,1991,65(5):535-540.
[36] KÁRPÁTI L,PENKE B,KATONA E,et al. A modified,optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma[J]. Clin Chem,2000,46(12):1946-1955.
[37] AJZNER E,MUSZBEK L.Kinetic spectrophotometric factor XIII activity assays:the subtraction of plasma blank is not omissible[corrected[J]. J Thromb Haemost,2004,2(11):2075-2077.
[38] DURDA M A,WOLBERG A S,KERLIN B A.State of the art in factor XIII laboratory assessment[J]. Transfus Apher Sci,2018,57(6):700-704.
[39] LIM W,MOFFAT K,HAYWARD C P M. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency[J]. J Thromb Haemost,2004,2(6):1017-1019.
[40] PARAMESWARAN K N,CHENG X F,CHEN E C,et al.Hydrolysis of gamma:Epsilon isopeptides by cytosolic transglutaminases and by coagulation factor XIII a[J]. J Biol Chem,1997,272(15):10311-10317.
[41] OERTEL K,HUNFELD A,SPECKER E,et al.A highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma[J]. Anal Biochem,2007,367(2):152-158.
[42] LEITNER M,BÜCHOLD C,PASTERNACK R,et al. Feasibility of an automated coagulation factor XIII a test using its isopeptidase activity[J]. Anal Biochem,2020,600:113757.
[43] LEITNER M,BÜCHOLD C,PASTERNACK R,et al. Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity[J]. Int J Mol Sci,2021,22(3):1002.
[44] HSU P,ZANTEK N D,MEIJER P,et al. Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency:an analysis of International Proficiency testing results[J]. Semin Thromb Hemost,2014,40(2):232-238.
[45] LI B J,BILLUR R,MAURER M C,et al.Proline 36 of the factor XIII activation peptide plays a crucial role in substrate recognition and zymogen activation[J]. Thromb Haemost,2018,118(12):2037-2045.
[46] KATONA E,HARAMURA G,KÁRPÁTI L,et al. A simple,quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2)[J]. Thromb Haemost,2000,83(2):268-273.
[47] BRIDEY F,NÉGRIER C,DUVAL C,et al. Impaired factor XIII activation in patients with congenital afibrinogenemia[J].Haematologica,2019,104(3):e111-e113.
[48] DORGALALEH A,RASHIDPANAH J.Blood coagulation factor XIII and factor XIII deficiency[J].Blood Rev,2016,30(6):461-475.
[49] DORGALALEH A.The history of factor XIII deficiency[J].Semin Thromb Hemost,2024,50(1):34-42.
[50] DORGALALEH A,BAHRAINI M,SHAMS M,et al.Molecular basis of rare congenital bleeding disorders[J]. Blood Rev,2023,59:101029.
[51] DORGALALEH A,TABIBIAN S,HOSSEINI S,et al.Guidelines for laboratory diagnosis of factor XIII deficiency[J]. Blood Coagul Fibrinolysis,2016,27(4):361-364.
[52] JANG M A,PARK Y S,LEE K O,et al.Novel and recurrent mutations in the F13A1 gene in unrelated Korean patients with congenital factor XIII deficiency[J]. Blood Coagul Fibrinolysis,2015,26(1):46-49.
[53] IVASKEVICIUS V,SEITZ R,KOHLER H P,et al.International registry on factor XIII deficiency:a basis formed mostly on European data[J]. Thromb Haemost,2007,97(6):914-921.
[54] KULKARNI B P,NAIR S B,VIJAPURKAR M,et al.Molecular pathology of rare bleeding disorders (RBDs) in India:a systematic review[J]. PLoS One,2014,9(9):e108683.
[55] STANDEVEN K F,CARTER A M,GRANT P J,et al.Functional analysis of fibrin{gamma}-chain cross-linking by activated factor XIII :determination of a cross-linking pattern that maximizes clot stiffness[J]. Blood,2007,110(3):902-907.
[56] MENEGATTI M,BIGUZZI E,PEYVANDI F.Management of rare acquired bleeding disorders[J]. Hematology Am Soc Hematol Educ Program,2019,2019(1):80-87.
[57] MILLER C H,PLATT S J,RICE A S,et al.Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance[J]. J Thromb Haemost,2012,10(6):1055-1061.
[58] MENEGATTI M,PALLA R,BOSCARINO M,et al.Minimal factor XIII activity level to prevent major spontaneous bleeds[J]. J Thromb Haemost,2017,15(9):1728-1736.
[59] MEIJER P.Clinically needed sensitivity for very low levels of factor XIII :not yet proven for a new functional assay[J]. Clin Chem Lab Med,2011,49(10):1753-1754.
[60] SMOCK K J,MOSER K A.Automation of a factor XIII activity assay utilizing a plasma blank measurement[J]. Methods Mol Biol,2023,2663:693-706.
[61] DUVAL C,ALI M,CHAUDHRY W W,et al. Factor XIII A-subunit V34L variant affects Thrombus cross-linking in a murine model of thrombosis[J]. Arterioscler Thromb Vasc Biol,2016,36(2):308-316.
[62] TSAI M,KITA A,LEACH J,et al.In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology[J]. J Clin Invest,2012,122(1):408-418.

凝血因子XIII检测的研究进展^*

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	李雨薇, 黄霞, 周源, 刘颖, 王林, 邹彬彬, 刘胡敏, 马海莉, 许婷婷, 唐飞, 曹铭静, 侯玲华, 李玉军, 胡文佳, 冯惟萍, 刘妍妍, 段勇, 温涛, 李明霞, 邱艳. 2018—2022年我国18家省级血液中心献血者HCV检测结果分析^*[J]. 临床输血与检验, 2024, 26(5): 638-644.
[2]	邓雪莲, 臧亮, 刘笑春, 孙鹏, 王颖颖, Daniel Candotti, 周俊. 基于HBV感染的确认探讨核酸检测反应性献血者的归队策略^*[J]. 临床输血与检验, 2024, 26(5): 667-674.
[3]	胡俊华, 韩剑峰, 王鹏, 夏荣, 刘凤华, 杨江存, 桂嵘, 刘娟, 秦莉, 杜春红, 李喜莹, 吕先萍, 殷鹏, 宫济武. HBV、HCV、HIV血筛多中心研究免疫学灰区的核酸检测分析与临床特征研究[J]. 临床输血与检验, 2024, 26(5): 675-679.
[4]	李素萍, 胡晓玉, 方烨, 陈志超, 蒋菲菲, 王婷. 献血者HEV感染合并HBV感染的特征分析^*[J]. 临床输血与检验, 2024, 26(4): 505-510.
[5]	王国美, 杨佶军, 刘铁梅. 胎母输血综合征检测方法与相关疾病的研究进展^*[J]. 临床输血与检验, 2024, 26(3): 426-432.
[6]	王涵, 王晓宁. 长春地区疑难血型的血清学检测和序列分析[J]. 临床输血与检验, 2023, 25(5): 619-624.
[7]	李小薇, 赵明明, 雷慧芬, 李翠莹. 1例RhCE抗原缺失型个体的分子机制研究[J]. 临床输血与检验, 2023, 25(5): 678-684.
[8]	李波, 曾祥龙. 献血者铁缺乏研究进展^*[J]. 临床输血与检验, 2023, 25(5): 699-705.
[9]	王斐, 陈要臻, 胡兴斌. 抗CD-38和抗CD-47单抗药物对输血相容性检测的干扰与应对策略研究进展^*[J]. 临床输血与检验, 2023, 25(4): 559-563.
[10]	李凤园, 袁玉华, 潘彤, 谢月娜, 徐姗. 天津地区核酸检测重复无反应性献血者HBV感染指标分析[J]. 临床输血与检验, 2023, 25(3): 395-400.
[11]	葛霜, 汪德清. 2021—2022年度输血医学研究进展^*[J]. 临床输血与检验, 2023, 25(2): 276-281.
[12]	谢君谋, 廖芬芳, 王淏, 杜荣松, 高文博, 郑优荣, 李仲平. 2例重复献血者HIV血清学检测窗口期追踪结果分析^*[J]. 临床输血与检验, 2022, 24(5): 647-650.
[13]	王利民, 丁宁, 臧思思, 刘善凤, 王平. 血小板光学检测技术对EDTA依赖性假性血小板减少的纠正性能分析[J]. 临床输血与检验, 2022, 24(4): 497-501.
[14]	中国输血协会人类组织抗原专业委员会, 中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识^*[J]. 临床输血与检验, 2022, 24(3): 273-278.
[15]	杨倩, 陆华, 徐婷. RhD抗原量子点荧光检测研究[J]. 临床输血与检验, 2022, 24(2): 188-192.